Drug Profile
Hydronidone - Gyre Therapeutics
Alternative Names: F-351Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Shanghai Genomics
- Developer Beijing Continent Pharmaceutical; Shanghai Genomics
- Class Antifibrotics; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Collagen inhibitors; Fibroblast growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hepatic fibrosis
- No development reported Non-alcoholic steatohepatitis; Renal failure
- Discontinued Pulmonary fibrosis
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in USA (PO, Capsule)
- 13 Nov 2023 Pharmacodynamics data from a preclinical studies in Hepatic fibrosis released by Gyre Therapeutics
- 13 Nov 2023 Gyre Therapeutics plans a phase II trial for Non-alcoholic Steatohepatitis (NASH) in USA in 2024